Oct. 9, 2011
On October 10, AstraZeneca announced its plan to invest $200 million into building a major new manufacturing facility in Taizhou’s China Medical City. The plant, which will produce both IV and solid oral medications for the China market, is the largest investment AstraZeneca has ever made in a single manufacturing site. Construction of the site is scheduled to be completed at the end of 2013. China is becoming increasingly important to AstraZeneca. In the first half of 2011, the company’s revenues in the PRC grew by 22% to $624 million.